Edgestream Partners L.P. Makes New $5.24 Million Investment in Abbott Laboratories $ABT

Edgestream Partners L.P. purchased a new stake in Abbott Laboratories (NYSE:ABT – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 53,011 shares of the healthcare product maker’s stock, valued at approximately $5,239,000.

A number of other institutional investors have also recently bought and sold shares of the company. Banco Santander S.A. grew its holdings in shares of Abbott Laboratories by 14.7% during the third quarter. Banco Santander S.A. now owns 34,716 shares of the healthcare product maker’s stock worth $3,431,000 after buying an additional 4,450 shares in the last quarter. First Financial Bankshares Inc increased its position in Abbott Laboratories by 2.6% during the third quarter. First Financial Bankshares Inc now owns 122,142 shares of the healthcare product maker’s stock worth $12,071,000 after purchasing an additional 3,131 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. raised its position in shares of Abbott Laboratories by 134.1% during the 3rd quarter. SBI Okasan Asset Management Co.Ltd. now owns 13,790 shares of the healthcare product maker’s stock valued at $1,392,000 after buying an additional 7,900 shares during the period. HighTower Advisors LLC raised its position in Abbott Laboratories by 0.7% in the third quarter. HighTower Advisors LLC now owns 1,597,358 shares of the healthcare product maker’s stock valued at $157,867,000 after purchasing an additional 11,677 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc lifted its position in Abbott Laboratories by 6.2% in the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 10,711 shares of the healthcare product maker’s stock valued at $1,059,000 after buying an additional 622 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABT. BTIG Research dropped their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. UBS Group lowered their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Barclays initiated coverage on shares of Abbott Laboratories in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock. Weiss Ratings raised Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Finally, Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $118.32.

Read Our Latest Report on Abbott Laboratories

Insider Activity

In other news, EVP Mary Moreland sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the sale, the executive vice president owned 100,791 shares of the company’s stock, valued at $11,691,756. The trade was a 3.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Down 0.2%

ABT stock opened at $104.48 on Thursday. The company has a market cap of $180.96 billion, a price-to-earnings ratio of 19.46, a price-to-earnings-growth ratio of 1.84 and a beta of 0.54. The company has a fifty day moving average price of $103.88 and a 200 day moving average price of $101.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $131.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The firm had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. During the same quarter last year, the company posted $1.30 earnings per share. The business’s revenue was up 14.5% on a year-over-year basis. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 94.03%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

See Also

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.